Leerink Partners analyst Roanna Ruiz reiterated a Buy rating on United Therapeutics (UTHR – Research Report) on February 11 and set a price target of $430.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Roanna Ruiz’s rating is based on the anticipation of multiple growth drivers that could positively impact United Therapeutics’ stock. Key among these is the potential expansion of Tyvaso into the idiopathic pulmonary fibrosis (IPF) market, with two significant Phase 3 trial results expected in 2025 and 2026. Furthermore, the company is seeing increased penetration of Tyvaso in the pulmonary hypertension associated with interstitial lung disease (PH-ILD) market and is making significant strides in organ manufacturing programs, which are approaching clinical trials.
Additionally, Roanna Ruiz highlights that United Therapeutics’ revenue and earnings per share estimates for the fourth quarter of 2024 are expected to surpass consensus, signaling strong financial performance. The company has also updated its valuation model for 2025, incorporating annual price increases for Tyvaso and other commercial products, leading to an increased price target of $430. These factors, combined with United Therapeutics’ robust commercial infrastructure and proactive efforts to maintain market competitiveness, support the Buy rating.
Ruiz covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Vir Biotechnology, and Lexicon Pharmaceuticals. According to TipRanks, Ruiz has an average return of -12.1% and a 32.99% success rate on recommended stocks.
In another report released on February 5, UBS also maintained a Buy rating on the stock with a $460.00 price target.